Literature DB >> 8706956

Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV).

K J Syrjänen1.   

Abstract

Because of the fact that any meaningful classification should bear a close relationship to the biological behavior of the lesions, the usefulness of all new classifications of cervical precancer lesions can only be established by well controlled prospective follow-up studies. However, several methodological and conceptual problems are encountered in the natural history studies conducted during the past several decades. While reviewing the available prospective follow-up studies on cervical intraepithelial neoplasia (CIN), Ostör (1993) found 3529 cases of CIN 1, of which 57% showed regression, persistence was found in 32%, progression to CIN III in 11%, and progression to invasive cancer in 1% of cases. The corresponding figures for CIN II were 43%, 35%, 22%, and 5%, respectively. The recognition of the association between human papillomavirus (HPV) and CIN has further complicated the assessment of the natural history of cervical precancer lesions. Results from the early prospective follow-up studies are remarkably consistent, however. Progression from HPV-NCIN (i.e., koilocytosis without CIN) to CIN I or greater was reported for 18 (8%) of 232 women followed by Syrjänen et al. for an average of 25 months, for 26 (8%) of 314 women followed by de Brux et al. (1981) for 15 to 18 months, and for 113 (13%) of 846 women followed for up to six years by Mitchell et al. During a 42-month follow-up period, 10% progression rate was found in 1269 women with HPV-CIN I, and in 17% of 762 women with HPV-CIN II by de Brux et al. (1983). The spontaneous regression rates were 53% and 39% in these cohorts, respectively. This is fully consonant with our experience from an almost 14-year follow-up of 530 women in Kuopio, where the spontaneous regression rate seems to increase in parallel with the extent of the follow-up time, currently being 66.7% for HPV-NCIN and 55.7% for HPV-CIN I. The figures for progression are 6.3% and 14.2%, respectively. It is obvious that the probability of a cervical precancer lesion to progress into an invasive disease increases with the severity of the atypia. Another distinct prognostic factor is HPV type, HPV 16 lesions possessing a significantly higher risk for progression than infections by other HPV types. The follow-up data also indicate, however, that even the high grade lesions may spontaneously regress, which should have important implications in therapy. The continuous problem still remains; these natural history observations only apply to a large series of women but are of little help in predicting the disease outcome in individual women.

Entities:  

Mesh:

Year:  1996        PMID: 8706956     DOI: 10.1016/0028-2243(95)02303-a

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  15 in total

1.  Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.

Authors:  A Lytwyn; J W Sellors; J B Mahony; D Daya; W Chapman; N Ellis; P Roth; A T Lorincz; A Gafni
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

2.  Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

Authors:  N R Chu; H B Wu; T Wu; L J Boux; M I Siegel; L A Mizzen
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 3.  [Modern biomarkers for precancerous lesions of the uterine cervix : Histological-cytological correlation and use].

Authors:  D Schmidt
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

4.  A study of anal intraepithelial neoplasia in HIV positive homosexual men.

Authors:  H B Lacey; G E Wilson; P Tilston; E G Wilkins; A S Bailey; G Corbitt; P M Green
Journal:  Sex Transm Infect       Date:  1999-06       Impact factor: 3.519

5.  Clinical Significance of Circulating Serum Levels of sCD95 and TNF-α in Cytoprotection of Cervical Cancer.

Authors:  Saurabh Kumar Agnihotri; Balawant Kumar; Ankita Jain; Anjali Anjali; Mahendra Pal Singh Negi; Rekha Sachan; Madan Lal Brahma Bhatt; Raj Kamal Tripathi; Monika Sachdev
Journal:  Rep Biochem Mol Biol       Date:  2022-01

6.  Methylation analysis of SFRP genes family in cervical adenocarcinoma.

Authors:  Ya-Wen Lin; Ming-Tzeung Chung; Hung-Cheng Lai; Ming De Yan; Yu-Leung Shih; Cheng-Chang Chang; Mu-Hsien Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-10       Impact factor: 4.553

7.  Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer.

Authors:  Gopeshwar Narayan; Luigi Scotto; Vijayalakshmi Neelakantan; Sherine H Kottoor; Ada Ho Yan Wong; Shee-Loong Loke; Mahesh Mansukhani; Bhavana Pothuri; Jason D Wright; Andreas M Kaufmann; Achim Schneider; Hugo Arias-Pulido; Qian Tao; Vundavalli V Murty
Journal:  Genes Chromosomes Cancer       Date:  2009-11       Impact factor: 5.006

8.  Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests.

Authors:  Steven L Kahn; Brigitte M Ronnett; Patti E Gravitt; Karen S Gustafson
Journal:  Cancer       Date:  2008-02-25       Impact factor: 6.860

9.  Clinicopathologic significance and treatment of ASC-US in cervical cytology.

Authors:  Asrar Mohammed Abdullah Abdulaziz; Lu Liu; Yu Sun; Xuewu You; Baoxia Cui; Sai Han; Youzhong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

Review 10.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.